Oracle Corp. shares surged Wednesday after the software giant reported better-than-expected third-quarter results and issued upbeat revenue guidance, while also unveiling a new clinical AI tool designed to streamline hospital documentation.

On Tuesday, Oracle posted third-quarter revenue of $17.19 billion, beating analyst estimates of $16.91 billion, according to Benzinga Pro. Adjusted earnings grew 21% year-over-year to $1.79 per share, beating analyst estimates of $1.71 per share.

Oracle expects fourth-quarter revenue to grow 18% to 20% on a year-over-year basis, roughly in line with estimates. It sees adjusted earnings per share of $1.96 and $2.00 in the fourth quarter, versus estimates of $1.95.

Several analysts made several updates to their ratings and price targets.

Don't Miss:

This AI Helps Fortune 1000 Brands Avoid Costly Ad Mistakes — See Why Investors Are Paying Attention

Explore the Fire-Safe Energy Storage Company With $185M in Contracted Revenue

Separately, the company said on Wednesday its Oracle Health Clinical AI Agent for automated note generation is now available in U.S. emergency departments and inpatient settings.

The tool automatically drafts clinical notes by capturing real-time patient interactions and pulling data from the Oracle Health Foundation electronic health record, including triage notes, lab results, and imaging information. Clinicians can review, edit, and finalize the notes.

Healthcare systems are already reporting efficiency gains. AtlantiCare expanded the tool across its emergency departments after earlier deployments reduced documentation time by 41%.

“Just as we saw in our ambulatory settings, we’re now seeing that same impact in the emergency department,” said Jordan Ruch, chief information officer at AtlantiCare.

Oracle said the AI system has saved physicians more than 200,000 hours across U.S. providers since launching just over a year ago.

Trending: Own the Characters, Not Just the Content: Inside a Fast-Growing Pre-IPO IP Company

The stock is currently trading 8.5% above its 20-day simple moving average (SMA) but is 2.3% below its 50-day SMA, indicating some short-term strength while facing resistance at the 50-day level. Over the past 12 months, shares have increased by 16.38% and are currently positioned closer to their 52-week highs than lows, suggesting a bullish trend.

The RSI is at 42.87, which is considered neutral territory, while the MACD shows a value of -4.5644, with a signal line at -6.1777, indicating a bullish crossover. This combination suggests that while the stock is not currently overbought, there is potential for upward momentum.

Key Resistance: $168.50

Key Support: $138.50

Oracle is expected to provide its next financial update on June 10, 2026.

EPS Estimate: $1.64 (Down from $1.70)

Revenue Estimate: $16.90 Billion (Up from $15.90 Billion)

Valuation: P/E of 28.1x (Indicates premium valuation)

See Also: This Under-$1 Pre-IPO AI Company Is Still Open to Retail Investors — Learn More

Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $251.64. Recent analyst moves include:

BMO Capital: Outperform (Lowers Target to $200.00) (Mar. 11)

TD Cowen: Buy (Maintains Target to $250.00) (Mar. 11)

RBC Capital: Sector Perform (Maintains Target to $160.00) (Mar. 11)

iShares Expanded Tech-Software Sector ETF (BATS:IGV): 7.37% Weight

First Trust NASDAQ Technology Dividend Index Fund (NASDAQ:TDIV): 5.44% Weight

Pacer Data and Digital Revolution ETF (NYSE:TRFK): 9.10% Weight

Significance: Because ORCL carries such a heavy weight in these funds, any significant inflows or outflows for these ETFs will likely force automatic buying or selling of the stock.

Read Next: It’s no wonder Jeff Bezos holds over $250 million in art — this alternative asset has outpaced the S&P 500 since 1995, delivering an average annual return of 11.4%. Here’s how everyday investors are getting started.

Photo via Shutterstock

Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market.

Get the latest stock analysis from Benzinga:

APPLE (AAPL): Free Stock Analysis Report

TESLA (TSLA): Free Stock Analysis Report

This article Goodbye, Grunt Work: Oracle's AI Just Reclaimed 200,000 Hours For Doctors originally appeared on Benzinga.com